Melbourne, May 28, 2010 (ABN Newswire) - Australia's regenerative medicine company, Mesoblast Limited (ASX:MSB) (ADR:MBLTY), was featured yesterday by the ASX at its inaugural Small to Mid Caps Conference in Singapore.
Mesoblast was one of only two emerging market leaders in the healthcare sector that were showcased to around 150 targeted global investors. The conference featured only 15 companies, predominantly from the resources sector, with market capitalisations of up to A$1 billion.
Chief Executive, Professor Silviu Itescu, updated investors on Mesoblast's acquisition of its United States associate company, Angioblast Systems, its near term growth strategies and plans for early product revenues.
Background
Mesoblast Limited is a world leader in commercialising biologic products for the broad field of regenerative medicine. Mesoblast has the worldwide exclusive rights for a series of patents and technologies developed over more than 10 years relating to the identification, extraction, culture and uses of adult Mesenchymal Precursor Cells (MPCs).
About Mesoblast Limited
Mesoblast Limited (ASX:MSB) (USOTC:MBLTY) is committed to the development of novel treatments for orthopaedic conditions, including the rapid commercialisation of a unique adult stem cell technology aimed at the regeneration and repair of bone and cartilage. Our focus is to progress through clinical trials and international regulatory processes necessary to commercialise the technology in as short a timeframe as possible. Mesoblast has the worldwide exclusive rights for a series of patents and technologies developed over more than 10 years relating to the identification, extraction and culture of adult Mesenchymal Precursor Cells (MPCs). The Company has acquired 38.4% of Angioblast Systems Inc., an American company developing the platform MPC technology for the treatment of cardiac, vascular and eye diseases including repair and regeneration of blood vessels and heart muscle. Mesoblast and Angioblast are jointly funding and progressing the core technology. Mesoblast's strategy is to maximise shareholder value through both corporate partnerships and the rapid and successful completion of clinical milestones.
ASX:MSB) (ADR:MBLTY), was featured yesterday by the ASX at its inaugural Small to Mid Caps Conference in Singapore.
Mesoblast Limited
){kind=link}